Results 211 to 220 of about 880,370 (262)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Abnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic. [PDF]

Lipids Health Dis
Davitadze M, Tsamalaidze A, Otiashvili D, Kvaratskhelia E, Butsashvili M.   +4 more
europepmc   +1 more source

CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads

Advanced Healthcare Materials, EarlyView.
In this paper researchers introduce CORE LNPs, a new class of lipid nanoparticles engineered to redirect mRNA expression away from the liver and into the spleen, a key immune organ. By combining chemical design with computational tools, they created cholesterol analogs that enable precise spleen‐targeted expression, providing greater applications for ...
Eshan A. Narasipura, Vincent Fung, Rachel VanKeulen‐Miller, Palas B. Tiwade, Owen S. Fenton   +4 more
wiley   +1 more source

Association of Fordyce's Granules with hyperlipidemia: A clinical indicator of lipid profile alterations. [PDF]

Bioinformation
Pandey A, Kumar S, Kumar A, Kumar A, Bharti A, Mani S, Saurabh S, Mittal M.   +7 more
europepmc   +1 more source

Ultrasound‐Triggered Nanobubbles for Endothelial‐Targeted Drug Delivery in the Detection and Treatment of Doxorubicin‐Induced Cardiotoxicity

Advanced Healthcare Materials, EarlyView.
The DA/VTP‐NBs selectively recognized cardiac ECs damaged by DIC and achieved cell‐level targeted imaging. Then US‐triggered controlled release successfully enabled the release of DAPA within the DA/VTP‐NBs at the site of injury. This precise on‐demand drug release approach amplifies a series of localized therapeutic effects through the mtDNA‐mediated ...
Jun Zhang, Yi Ling, Xin Li, Deng Liu, Li Dong, Xuemei Chen, Yingxin Sun, Yongning Shang, Yanli Guo   +8 more
wiley   +1 more source

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

Advanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen, Neona M. Lowe, Sophia Kellogg, Kuan‐Wei Huang, Hannah O'Toole, Elizabeth J. Hale, Venktesh S. Shirure, Bhupinder S. Shergill, Steven C. George, Randy P. Carney   +9 more
wiley   +1 more source

An Altered Lipid Profile Is Indicative of Increased Insulin Requirement in Children and Adolescents at the Onset of Type 1 Diabetes. [PDF]

J Pers Med
Maltoni G, Bernardini L, Scozzarella A, Montanari G, Cantarelli E, Lanari M.   +5 more
europepmc   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

Integrated SIRI and Lipid Profile for Early Prediction of Bloodstream Infection in AML During Induction Chemotherapy. [PDF]

Infect Drug Resist
Luo G, Zeng S, Zhao H.
europepmc   +1 more source